Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
NCT04938830Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of clesrovimab-cfor in respiratory syncytial virus infection (RSV), sponsored by Merck & Co.. Started Nov 2021; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04938830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938830.